Introduction
Methods
Study design and patients
IVUS imaging
Measurements of conventional and IB-IVUS parameters
Statistical analysis
Results
Study populations
Baseline clinical characteristics
CKD-1 (n = 18) | CKD-2 (n = 42) | CKD-3 (n = 29) | CKD4–5 (n = 24) |
p value | |
---|---|---|---|---|---|
Age | 61 ± 12 | 70 ± 9 | 77 ± 9 | 69 ± 9 | <0.0001 |
Male sex | 16 (89) | 27 (64) | 20 (69) | 18 (75) | 0.2 |
BMI (kg/m2) | 23.4 ± 3.6 | 24.3 ± 3.3 | 23.9 ± 3.6 | 22.2 ± 3.4 | 0.1 |
Unstable angina pectoris | 10 (56) | 10 (24) | 6 (21) | 1 (4) | 0.001 |
Hypertension | 13 (72) | 32 (76) | 22 (76) | 20 (83) | 0.8 |
Hyperlipidemia | 8 (44) | 26 (62) | 13 (45) | 16 (67) | 0.2 |
Diabetes mellitus | 7 (39) | 11 (26) | 13 (45) | 18 (75) | 0.002 |
Current smoking | 7 (39) | 11 (26) | 9 (31) | 10 (42) | 0.6 |
Baseline biochemistry data | |||||
LDL cholesterol (mg/dl) | 113 ± 35 | 105 ± 35 | 101 ± 29 | 101 ± 38 | 0.6 |
HDL cholesterol (mg/dl) | 52 ± 11 | 54 ± 14 | 56 ± 15 | 47 ± 13 | 0.1 |
HbA1c (%) | 6.3 ± 1.2 | 6.3 ± 1.1 | 6.2 ± 0.7 | 6.6 ± 1.2 | 0.6 |
hs CRP (mg/dl) | 0.5 ± 0.9 | 0.7 ± 1.9 | 0.4 ± 0.9 | 0.6 ± 1.6 | 0.8 |
SBP (mmHg) | 137 ± 22 | 130 ± 19 | 133 ± 19 | 140 ± 22 | 0.2 |
DBP (mmHg) | 84 ± 15 | 72 ± 14 | 74 ± 13 | 75 ± 14 | 0.03 |
Follow-up period (months) | 7.2 ± 1.9 | 8.0 ± 1.7 | 7.8 ± 1.3 | 8.1 ± 1.9 | 0.3 |
Lesion location (%) | |||||
LAD/LCX/RCA | 55/17/28 | 60/5/36 | 52/31/17 | 46/13/42 | 0.07 |
Risk factor control
CKD-1 | CKD-2 | CKD-3 | CKD4–5 |
p value | |
---|---|---|---|---|---|
Medications after PCI | |||||
Statin | 15 (84) | 40 (95) | 26 (90) | 21 (85) | 0.24 |
(Continue statin group: CS) | 4 (22) | 14 (33) | 10 (34) | 11 (46) | 0.45 |
(Initiate statin group: IS) | 11 (61) | 26 (62) | 16 (55) | 10 (42) | 0.79 |
β-blocker | 8 (44) | 12 (29) | 18 (62) | 12 (50) | 0.04 |
DAPT | 60 (100) | 33 (100) | 20 (100) | 20 (100) | – |
ACE-I/ARB | 13 (72) | 25 (60) | 20 (69) | 17 (71) | 0.7 |
Clinical data at follow-up | |||||
LDL cholesterol (mg/dl) | 96 ± 19 | 87 ± 26 | 81 ± 18 | 87 ± 34 | 0.3 |
HDL cholesterol (mg/dl) | 54 ± 11 | 55 ± 14 | 55 ± 15 | 47 ± 13 | 0.1 |
HbA1c (%) | 6.3 ± 1.2 | 6.2 ± 1.0 | 6.2 ± 0.7 | 6.9 ± 1.3 | 0.03 |
CRP (mg/dl) | 0.2 ± 0.2 | 0.2 ± 0.9 | 0.1 ± 0.1 | 0.3 ± 0.4 | 0.6 |
SBP (mmHg) | 120 ± 15 | 119 ± 13 | 130 ± 23 | 133 ± 20 | 0.008 |
DBP (mmHg) | 72 ± 15 | 67 ± 10 | 73 ± 15 | 71 ± 12 | 0.3 |
Change from baseline | |||||
LDL cholesterol (mg/dl) | −17 ± 37 | −19 ± 33 | −20 ± 28 | −15 ± 46 | 0.9 |
HDL cholesterol (mg/dl) | +2 ± 7 | +1 ± 10 | 0 ± 9 | 0 ± 11 | 0.9 |
HbA1c (%) | 0 ± 0.4 | 0 ± 0.8 | 0 ± 0.7 | +0.4 ± 0.8 | 0.06 |
CRP (mg/dl) | −0.4 ± 0.7 | −0.4 ± 1.5 | −0.2 ± 0.9 | −0.3 ± 1.6 | 0.9 |
SBP (mmHg) | −16 ± 23 | −10 ± 22 | −3 ± 24 | −8 ± 32 | 0.3 |
DBP (mmHg) | −12 ± 15 | −5 ± 14 | −1 ± 13 | −4 ± 16 | 0.1 |
Achievement ratio of target control level at follow-up | |||||
LDL cholesterol <100 mg/dl | 10 (55) | 31 (74) | 24 (83) | 16 (67) | 0.2 |
HDL cholesterol >40 mg/dl | 17 (94) | 37 (88) | 22 (76) | 17 (71) | 0.1 |
HbA1c <7.0 % | 15 (83) | 39 (93) | 24 (83) | 12 (50) | 0.03 |
SBP <140 mmHg | 16 (89) | 40 (95) | 22 (76) | 17 (71) | 0.03 |
DBP <80 mmHg | 12 (67) | 36 (86) | 21 (72) | 20 (83) | 0.3 |
Conventional IVUS analysis
Volume (mm3) | CKD-1 | CKD-2 | CKD-3 | CKD4–5 |
p value |
---|---|---|---|---|---|
EEM | |||||
Baseline | 88.8 ± 21.3 | 80.0 ± 23.3 | 78.2 ± 21.1 | 93.1 ± 19.7c,e
| 0.039 |
Follow-up | 86.5 ± 24.5 | 78.3 ± 24.2 | 79.6 ± 16.0 | 99.1 ± 22.9d,f
| 0.002 |
Lumen | |||||
Baseline | 54.2 ± 15.3 | 44.0 ± 19.7 | 42.5 ± 17.5 | 47.4 ± 13.2 | 0.121 |
Follow-up | 57.3 ± 18.0 | 45.6 ± 20.1a
| 38.4 ± 12.1b
| 43.6 ± 15.8a
| 0.004 |
Plaque | |||||
Baseline | 34.7 ± 14.2 | 35.9 ± 12.1 | 35.6 ± 9.1 | 45.8 ± 16.3b,d,e
| 0.009 |
Follow-up | 29.2 ± 11.9 | 32.7 ± 11.1 | 40.2 ± 7.9b,c
| 55.6 ± 19.3b,d,f
| <0.001 |
Variable | Odds ratio | 95 % CI |
p value |
---|---|---|---|
CKD stage 1 | Reference | ||
CKD stage 2 | 0.95 | 0.25–3.62 | 0.945 |
CKD stage 3–5 | 15.1 | 4.07–55.6 | <0.0001 |
Age | 1.02 | 0.98–1.06 | 0.300 |
Gender | 1.38 | 0.61–3.15 | 0.438 |
BMI | 0.97 | 0.87–1.07 | 0.513 |
UAP | 0.26 | 0.10–0.69 | 0.007 |
Current smoking | 1.11 | 0.51–2.44 | 0.790 |
Follow-up SBP >140 mmHg | 1.02 | 1.00–1.04 | 0.122 |
Follow-up LDL >100 mg/dl | 1.00 | 0.98–1.01 | 0.737 |
Follow-up HbA1c >7.0 % | 1.56 | 1.04–2.34 | 0.032 |
ACE-I/ARB use | 0.71 | 0.32–1.55 | 0.389 |
Β-blocker use | 2.13 | 1.00–4.55 | 0.049 |
Statin use | 0.53 | 0.15–1.92 | 0.332 |
Variable | Odds ratio | 95 % CI |
p value |
---|---|---|---|
CKD stage 1 | Reference | ||
CKD stage 2 | 0.93 | 0.21–4.14 | 0.928 |
CKD stage 3–5 | 13.56 | 2.85–64.44 | 0.001 |
Age | 0.98 | 0.94–1.04 | 0.631 |
Gender | 1.67 | 0.55–5.11 | 0.367 |
UAP | 0.39 | 0.11–1.32 | 0.129 |
Follow-up HbA1c >7.0 % | 1.36 | 0.87–2.12 | 0.178 |
Β-blocker use | 1.38 | 0.51–3.70 | 0.524 |
IB-IVUS analysis
Volume | CKD-1 (n = 15) | CKD-2 (n = 33) | CKD-3 (n = 23) | CKD4–5 (n = 22) |
p value |
---|---|---|---|---|---|
Calcification | |||||
Baseline | |||||
% | 1.0 ± 1.5 | 1.2 ± 1.3 | 1.5 ± 1.6 | 2.5 ± 2.4b,d
| 0.02 |
mm3
| 0.3 ± 0.4 | 0.4 ± 0.6 | 0.6 ± 0.9 | 1.3 ± 1.5b,d,f
| 0.002 |
Follow-up | |||||
% | 1.1 ± 2.0 | 1.8 ± 2.4 | 1.5 ± 1.7 | 2.4 ± 2.2 | 0.33 |
mm3
| 0.3 ± 0.5 | 0.6 ± 0.7 | 0.6 ± 0.6 | 1.6 ± 1.8b,d,f
| <0.001 |
Dense-fibrous | |||||
Baseline | |||||
% | 3.5 ± 1.9 | 3.8 ± 2.4 | 5.1 ± 3.1 | 5.0 ± 2.3 | 0.10 |
mm3
| 1.3 ± 0.8 | 1.3 ± 0.8 | 1.8 ± 1.2 | 2.4 ± 1.8b,d
| 0.005 |
Follow-up | |||||
% | 3.8 ± 3.0 | 4.7 ± 3.3 | 4.3 ± 2.5 | 5.1 ± 2.4 | 0.55 |
mm3
| 1.1 ± 0.9 | 1.5 ± 1.3 | 1.7 ± 1.1 | 3.1 ± 2.1b,d,f
| <0.001 |
Fibrous | |||||
Baseline | |||||
% | 45.0 ± 8.7 | 38.7 ± 11.2 | 43.5 ± 10.1 | 39.2 ± 8.3 | 0.12 |
mm3
| 16.1 ± 7.2 | 13.4 ± 5.1 | 15.7 ± 5.2 | 17.3 ± 4.7c
| 0.066 |
Follow-up | |||||
% | 43.6 ± 9.8 | 40.6 ± 11.5 | 37.6 ± 11.2 | 38.3 ± 9.9 | 0.34 |
mm3
| 12.8 ± 4.8 | 12.8 ± 5.9 | 14.9 ± 5.9 | 20.7 ± 6.3b,d,f
| <0.001 |
Lipid | |||||
Baseline | |||||
% | 50.5 ± 10.6 | 54.2 ± 12.9 | 49.9 ± 12.4 | 53.4 ± 8.4 | 0.53 |
mm3
| 18.3 ± 8.3 | 20.2 ± 9.7 | 18.0 ± 6.5 | 25.7 ± 10.5a,c,f
| 0.024 |
Follow-up | |||||
% | 51.5 ± 12.6 | 53.0 ± 14.5 | 56.6 ± 13.0 | 54.2 ± 10.4 | 0.65 |
mm3
| 15.8 ± 9.6 | 17.5 ± 8.7 | 22.6 ± 7.1a
| 31.1 ± 12.6b,d,f
| <0.001 |